Haiyun Xiong
Overview
Explore the profile of Haiyun Xiong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li J, Zhang Q, Guan Y, Liao D, Chen H, Xiong H, et al.
Cell Death Dis
. 2024 Apr;
15(4):240.
PMID: 38561354
Abnormal lipid metabolism and lipid accumulation are characteristic hallmarks of renal cell carcinoma (RCC). While there is prior evidence closely linking such lipid accumulation within RCC cells and consequent tumorigenesis,...
2.
Zhang W, Yu L, Chang Z, Xiong H
J Cancer
. 2024 Jan;
15(3):623-631.
PMID: 38213738
Bladder instillation therapy is a common treatment for superficial or nonmuscle invasive bladder cancer. After surgery or reresection, chemotherapy drugs (epirubicin) or medications such as Bacillus Calmette-Guérin (BCG) are used...
3.
Li J, Zhang Q, Guan Y, Liao D, Jiang D, Xiong H, et al.
Cell Death Dis
. 2022 May;
13(5):443.
PMID: 35525866
Metabolic dysfunction is seen in cancer cells where increased glycolysis provides energy for growth. Circular RNAs (circRNAs) are thought to assist in glucose metabolism and the switch to glycolysis. Through...
4.
Zhang S, Zheng W, Jiang D, Xiong H, Liao G, Yang X, et al.
Front Oncol
. 2021 May;
11:575425.
PMID: 33937014
Background: Recent research of clear cell renal cell carcinoma (ccRCC) is focused on the tumor immune microenvironment (TIME). Chromatin accessibility is critical for regulation of gene expression. However, its role...
5.
Yang Y, Jiang D, Zhou Z, Xiong H, Yang X, Peng G, et al.
Cell Oncol (Dordr)
. 2021 Apr;
44(4):871-887.
PMID: 33905040
Purpose: Transcriptional addiction plays a pivotal role in maintaining the hallmarks of cancer cells. Thus, targeting super-enhancers (SEs), which modulate the transcriptional activity of oncogenes, has become an attractive strategy...
6.
Zhang L, Zhang S, Li M, Li Y, Xiong H, Jiang D, et al.
Mater Sci Eng C Mater Biol Appl
. 2021 Apr;
123:111956.
PMID: 33812584
Docetaxel (DTX)-based chemotherapy of prostate cancer is still confronted with significant challenges due to insufficient drug accumulation at the tumor sites and the systemic side effects on normal cells and...
7.
Tong T, Guan Y, Xiong H, Wang L, Pang J
Front Oncol
. 2020 Oct;
10:1541.
PMID: 33042799
Accumulative studies suggest the Glasgow prognostic score (GPS) and modified Glasgow prognostic score (mGPS) to be potential biomarkers; however, their prognostic value remains debatable. Our meta-analysis focused on assessing the...
8.
Liao G, Xiong H, Tang J, Li Y, Liu Y
Technol Cancer Res Treat
. 2020 Sep;
19:1533033820959354.
PMID: 32930086
MicroRNAs (miRNAs) was confirmed to play an active role in the pathogenesis of prostate cancer (PCa). The expression and biological function for miR-92a in PCa remains unknown. In this study,...
9.
Li J, Jiang D, Zhang Q, Peng S, Liao G, Yang X, et al.
Cancer Manag Res
. 2020 Jul;
12:4309-4320.
PMID: 32606927
Objective: Renal cell carcinoma (RCC) displays an increasing incidence and mortality rate worldwide in recent years. More and more evidence demonstrated microRNAs function as positive or negative regulatory factors in...
10.
Liao G, Tang J, Wang D, Zuo H, Zhang Q, Liu Y, et al.
World J Surg Oncol
. 2020 May;
18(1):81.
PMID: 32357938
Objectives: This research aimed to examine the antitumor mechanisms of selenium nanoparticles (SeNPs) specifically against prostate cancers. Methods: The antitumor activities of SeNPs against cancer cells were determined via MTT...